Business Wire

Radisys Introduces White Box Combo PON Optical Line Terminals for Next-Gen FTTX Networks

13.7.2021 15:00:00 EEST | Business Wire | Press release

Share

Radisys® Corporation, a global leader of open telecom solutions, today introduced the Radisys Combo PON Optical Line Terminal (OLT) as part of the Radisys Connect Open Broadband portfolio for broadband service providers. The complete family of Radisys OLTs includes 16 and 32-port versions—a variant of which is the Radisys white box Combo PON OLT that supports both G-PON (2.488 Gbps downstream / 1.244 Gbps upstream) and XGS-PON (10 Gbps symmetrical) within the same PON port of the OLT. The white box OLTs are based on the VOLTHA/SEBA reference architecture and are field-hardened and scaled for commercial deployments today.

News Highlights

  • A growing number of global service providers are moving forward with XGS-PON as their next-generation PON technology of choice. Analyst firm Dell-Oro Group predicts XGS-PON will be the favored PON technology for the future.
  • Radisys’ Combo PON OLT allows broadband providers to take advantage of pervasive G-PON technology while giving them a flexible upgrade path to scale up and rollout XGS-PON deployments without costly rip and replace.
  • Radisys’ Combo PON OLT is an open, flexible, highly scalable telco-grade white box designed to address service providers’ key needs.
    • Full PON port flexibility enables G-PON, XGS-PON or Combo PON (G-PON and XGS-PON) on any port on the same platform.
    • Open architecture delivers datacenter-driven cost efficiencies and high port densities, making it suitable for residential, cloud and enterprise services to simplify deployments and reduce operating expenses.
    • Compatibility with any ONF VOLTHA-based software, including Radisys’ Connect Broadband Access Controller (CBAC) software, allows service providers to scale hardware up or down while the management software and all other Connect Open Broadband components remain intact.
    • Flexibility to deploy virtualized functions either in a distributed fashion running within the OLT CPU, or as a centralized function hosted on an external server or a public or private cloud.
  • Radisys’ Combo PON OLTs are part of the Connect Open Broadband product suite, which includes open and disaggregated software, hardware and management.
  • The complete family of Radisys OLTs also includes the 16 and 32-port OLTs. The Radisys 32 port G-PON OLT (RLT-3200G) was recently certified for VOLTHA v2.8 through Open Networking Foundation’s Continuous Certification Program.

“Radisys’ Combo PON OLTs give broadband providers an optimal economic advantage with the flexibility to use both G-PON and XGS-PON in their networks and through a reduction in space and power consumption,” said Harris Razak, senior vice president of Broadband Access, Radisys. “All products in the Connect Open Broadband portfolio utilize the same management system and controlling software, allowing our provider customers to choose the features and capacity they want while keeping other network elements the same, lowering their total cost of ownership and optimizing their Capex and Opex.”

“We are pleased that Radisys’ 32-port G-PON OLT has been named a certified VOLTHA product within the ONF Continuous Certification Program. This certification, along with the introduction of the Radisys Combo PON OLT with support for VOLTHA/SEBA, offers broadband service providers with greater solution choices for their FTTX deployments,” said Guru Parulkar, ONF Executive Director. “As an ONF Partner Member, Radisys has been instrumental in the development of ONF open reference designs as well as the commercialization of ONF-based solutions. The Continuous Certification Program ensures that service providers can easily identify certified products for specific ONF projects within a vibrant ecosystem of vendors delivering and deploying ONF open source platforms.”

About Radisys

Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.Radisys.com.

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nereus for Radisys
Lori Mesecke, +1-503-459-9150
lmesecke@nereus-worldwide.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye